Centiva Capital LP Sells 8,689 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Centiva Capital LP cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 48.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 9,144 shares of the medical equipment provider’s stock after selling 8,689 shares during the quarter. Centiva Capital LP’s holdings in Lantheus were worth $1,004,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Farallon Capital Management LLC lifted its stake in shares of Lantheus by 53.7% in the 2nd quarter. Farallon Capital Management LLC now owns 2,279,227 shares of the medical equipment provider’s stock valued at $182,999,000 after purchasing an additional 796,000 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Lantheus during the 2nd quarter valued at $26,794,000. Massachusetts Financial Services Co. MA purchased a new stake in shares of Lantheus in the 3rd quarter worth about $25,955,000. Swedbank AB lifted its position in Lantheus by 40.9% during the 2nd quarter. Swedbank AB now owns 596,400 shares of the medical equipment provider’s stock valued at $47,885,000 after acquiring an additional 173,100 shares during the period. Finally, LSV Asset Management boosted its stake in Lantheus by 27.9% during the second quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock worth $51,462,000 after acquiring an additional 139,647 shares in the last quarter. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

Lantheus stock opened at $89.34 on Friday. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89. The business’s fifty day moving average is $99.75 and its 200 day moving average is $97.38. The stock has a market capitalization of $6.21 billion, a PE ratio of 14.87 and a beta of 0.45.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Truist Financial reiterated a “buy” rating and set a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities dropped their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a report on Thursday, November 7th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $130.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.